CIENCIASMEDICASNEWS: FDA approves sodium thiosulfate to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors | FDA

miércoles, 21 de septiembre de 2022

FDA approves sodium thiosulfate to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors | FDA

FDA approves sodium thiosulfate to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors | FDA

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)